Company Overview
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.09.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -24.34% |
| 6 Months: | +4.88% |
| 3 Months: | -14.00% |
| 1 Month: | +10.73% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.73 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 41.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VERU Veru Inc. PHARMA | 2.58 | -4.23 | $43.99M | 0.00% | - | -64.54% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.59M | 2.57M | 5.50M | 6.37M | 6.98M | 9.73M | 10.58M | 9.94M | 10.32M | 14.62M | 13.34M | 17.66M | 14.14M | 13.03M | 9.60M | 2.51M | 6.59M | 3.34M | 2.14M | 4.14M | 3.95M | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 2.89M | 3.82M | 6.39M | 4.63M | 4.12M | 5.40M | 2.85M | 3.23M | 1.87M | 1.65M | 1.28M | 2.29M | 1.79M | 1.31M | 1.20M | 3.07M | 4.64M | 4.61M | 6.57M | 7.27M | 7.44M | 6.52M | 10.84M | 10.91M | 13.87M | 11.84M | 11.18M | 7.07M | 702.05K | 4.09M | 1.23M | 1.15M | 678.30K | 1.34M | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.10M | 8.03M | 7.46M | 5.42M | 7.22M |
| Operating Income | - | 1.45M | 2.95M | 1.45M | - | 2.39M | 70.42K | 848.52K | - | -1.87M | -2.58M | -1.27M | - | -7.44M | -4.70M | -4.96M | -1.01M | -2.12M | -1.84M | -1.78M | -299.68K | -1.39M | 19.19M | -1.47M | -2.87M | -4.96M | -11.76M | -21.82M | -37.45M | -34.41M | -13.74M | -7.39M | -8.89M | -10.55M | - | -9.10M | -8.03M | -7.46M | -5.42M | -7.22M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.07M | -8.00M | -7.43M | -5.40M | -7.19M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.85M | -7.32M | 1.30M | -5.33M | -3.09M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -566.12K | 804.92K | 1.67M | 1.17M | 702.57K | 1.49M | 35.05K | 570.26K | -1.75M | -1.37M | -1.78M | -789.89K | -2.68M | -4.26M | -3.83M | -7.93M | -2.15M | -4.03M | -2.77M | -3.31M | -810.51K | -3.03M | 17.23M | -2.85M | -2.69M | -6.38M | -14.18M | -22.20M | -38.71M | -33.79M | -12.52M | -8.28M | -10.03M | -10.97M | - | -7.90M | -7.33M | 1.45M | -5.33M | -2.74M |
| Diluted EPS | -0.02 | 0.03 | 0.06 | 0.04 | 0.02 | 0.05 | 0.00 | 0.02 | -0.06 | -0.04 | -0.06 | -0.03 | -0.12 | - | - | - | - | - | - | -0.05 | -0.01 | -0.05 | 0.23 | -0.04 | -0.03 | -0.08 | -0.18 | -0.28 | -0.48 | -0.42 | 0.07 | -0.08 | -0.07 | - | -0.60 | -0.50 | -0.50 | - | -0.26 | -0.12 |
| R&D Expense | - | - | - | - | - | - | 35.12K | 22.72K | - | 171.10K | 1.21M | 302.07K | - | 1.96M | 2.08M | 3.79M | 2.36M | 2.91M | 4.87M | 5.30M | 3.93M | 4.44M | 5.68M | 7.57M | 11.19M | 10.08M | 15.54M | 18.13M | 20.61M | 17.86M | 8.79M | 1.66M | 2.99M | 4.85M | 5.72M | 3.93M | 3.02M | - | 1.34M | 3.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.54M | 22.22M | 18.57K | 35.03M | 31.46M | 24.49M | 32.60M | 22.13M | 13.66M | 15.86M | 31.80M | 42.59M | - | 39.35M | 16.30M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 13.33M | 8.76M | 8.73M | 11.03M | - |
| Gross Profit | 13.52M | 12.92M | 9.87M | 20.62M | 17.50M | 13.12M | 18.97M | 13.35M | 7.02M | 8.77M | 21.66M | 30.79M | 47.93M | 30.59M | 7.57M | 5.85M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 114.08M | 103.17M | 37.39M | 35.53M |
| Operating Income | 4.72M | 4.35M | 3.30M | 10.94M | 9.79M | 3.92M | 6.62M | 3.02M | -8.49M | -20.87M | -6.44M | -14.75M | - | -83.49M | -95.61M | -37.39M | -35.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -79.23M | -89.98M | -37.12M | -35.38M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 4.85M | 4.37M | 2.43M | 607.47K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -83.80M | -92.67M | -35.26M | -15.68M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -3.13M | 236.40K | 480.21K | 725.10K | - |
| Net Income | 6.54M | 6.74M | 5.40M | 15.30M | 14.34M | 2.43M | 4.35M | 344.73K | -6.61M | -23.94M | -12.02M | -18.97M | - | -84.04M | -93.15M | -37.80M | -22.73M |
| Diluted EPS | 0.24 | 0.24 | 0.19 | 0.53 | 0.50 | 0.08 | 0.15 | 0.01 | -0.25 | - | - | -0.28 | - | -10.50 | -11.00 | -2.80 | -1.55 |
| R&D Expense | 105.92K | 381 | 10.93K | 5.28K | 4.75K | 5.58K | 219.81K | 99.39K | 3.08M | 10.85M | 13.74M | 16.94M | 32.69M | 70.65M | 51.20M | 12.78M | 15.59M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 18.37M | 19.44M | 30.45M | 35.17M | 31.67M | 37.47M | 38.62M | 55.34M | 48.45M | 53.63M | 51.54M | - | 135.36M | 50.02M | 60.42M | 29.84M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 104.00M | 22.93M | 35.22M | 18.92M |
| Cash & Equivalents | 1.92M | 2.81M | 2.92M | 4.25M | 5.30M | 8.92M | 5.80M | 4.11M | - | - | - | - | - | - | 80.19M | 9.63M | 24.92M | 15.79M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.57M | 8.62M | 6.70M | 4.14M | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.79M | 3.55M | 4.51M | 3.96M | - |
| Total Liabilities | - | - | 2.24M | 2.69M | 6.23M | 3.77M | 3.61M | 4.34M | 4.69M | 6.88M | 18.97M | 21.30M | 21.43M | - | 52.56M | 30.34M | 28.10M | 11.50M |
| Current Liabilities | - | - | 1.94M | 2.29M | 5.86M | 3.47M | 3.38M | 4.23M | 3.35M | 5.49M | 13.55M | 14.02M | 14.73M | - | 38.71M | 17.81M | 11.87M | 7.79M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 1.75M | - | - | 9.40M | 9.66M | 8.87M | 8.85M | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.88M | 14.41M | 13.52M | 3.12M |
| Total Equity | 9.71M | 12.95M | 16.13M | 16.75M | 24.22M | 31.40M | 28.07M | 33.13M | 33.93M | 48.45M | 29.48M | 32.33M | 30.11M | - | 82.80M | 19.68M | 32.32M | 18.33M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.27M | 9.40M | 14.86M | 14.87M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.75M | 3.99M | 6.97M | 10.36M | 11.79M | - | - | - | 982.89K | -11.55M | -5.49M | -1.93M | - | -47.51M | -88.01M | -21.68M | -30.04M |
| Investing Cash Flow | -1.50M | 49.36K | -46.29K | -654.18K | -302.20K | - | - | - | -90.37K | -50.65K | -108.52K | -105.76K | - | 4.27M | 6.33M | 146.21K | 25.14M |
| Financing Cash Flow | -3.24M | -3.93M | -5.59M | -8.66M | -7.86M | - | - | - | - | 12.08M | 8.13M | 9.33M | - | 1.07M | 11.11M | 36.83M | -4.22M |
| Capital Expenditure | -1.64M | -51.13K | -46.29K | -718.30K | -302.20K | -97.31K | -135.42K | -6.37K | -133.49K | -50.65K | -108.52K | -105.76K | - | -733.05K | -665.70K | -158.32K | -1.08K |
| Free Cash Flow | 4.10M | 3.94M | 6.92M | 9.64M | 11.49M | - | - | - | 849.40K | -11.60M | -5.59M | -2.04M | - | -48.24M | -88.68M | -21.84M | -30.04M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -42.17M | -70.57M | 15.29M | -9.12M |
| Share Buybacks | 3.83M | 349.06K | 33.06K | 289.61K | 395.67K | 737.75K | 950 | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | - | 6.20M | 5.50M | 6.20M | 7.50M | 6.10M | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 49.1% | 58.2% | 53,138.6% | 58.9% | 55.6% | 53.6% | 58.2% | 60.3% | 51.4% | 55.3% | 68.1% | 72.3% | - | 77.7% | 46.4% | - | - |
| Operating Margin % | 17.1% | 19.6% | 17,750.3% | 31.2% | 31.1% | 16.0% | 20.3% | 13.6% | -62.2% | -131.6% | -20.2% | -34.6% | - | -212.1% | -586.6% | - | - |
| Net Margin % | 23.7% | 30.3% | 29,081.9% | 43.7% | 45.6% | 9.9% | 13.3% | 1.6% | -48.4% | -150.9% | -37.8% | -44.5% | - | -213.5% | -571.6% | - | - |
| ROE % | 50.4% | 41.8% | 32.2% | 63.2% | 45.7% | 8.7% | 13.1% | 1.0% | -13.6% | -81.2% | -37.2% | -63.0% | - | -101.5% | -473.4% | -117.0% | -124.0% |
| ROCE % | - | 26.5% | 19.2% | 44.5% | 30.9% | 13.9% | 19.9% | 8.6% | -17.0% | -59.8% | -16.2% | -40.1% | - | -86.4% | -296.8% | -77.0% | -161.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 4.10% | 698.44K | $1.68M |
| 2 | Alyeska Investment Group, L.p. | 1.40% | 238.56K | $574.92K |
| 3 | Oppenheimer & Co Inc | 1.24% | 210.84K | $508.13K |
| 4 | Blackrock Inc. | 0.98% | 167.08K | $402.67K |
| 5 | Renaissance Technologies, LLC | 0.96% | 164.45K | $396.32K |
| 6 | GSA Capital Partners LLP | 0.92% | 157.34K | $379.18K |
| 7 | Geode Capital Management, LLC | 0.91% | 155.08K | $373.73K |
| 8 | Summit Financial, LLC | 0.83% | 141.87K | $341.89K |
| 9 | Jane Street Group, LLC | 0.75% | 127.85K | $308.12K |
| 10 | FNY Investment Advisers, LLC | 0.62% | 105.08K | $253.25K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VERU
Veru Stock Price Forecast. Should You Buy VERU? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5TWUZkZXRGazJxQUxqNVdQRnp6MGhXUXI5Uk1odExDQmJPOU5OME95NkhqVi1LTWJYMHZNa0t0NFpMMVBGTUJBSw?oc=5" target="_blank">Veru Stock Price Forecast. Should You Buy VERU?</a> <font …
Veru Inc. Announces Sabizabulin Overcomes Daraxonrasib Resistance in Preclinical Pancreatic Cancer Studies and Advances Phase 2b Development Plan - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxQMV9rWGtucjZlRXZjM1QzSDNKbGtERXl6dnh6bW5OdG9xMU5ZaE04eXh3RllEOGlMRTJmOHZ6cVh1blFTZUVxMzIwNHBISWw0Y0N4djBGNWFWSk9NZkNVdXFWVXBtRUd2VXg0a1VmQ0FIeHlLdFNfSHIyS3N2ZjJWVFZadDVsM3ZZYWlVLV…
Veru (VERU) chief scientist adds 1,800 shares in open-market buy - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQWGl0bnhkYjd1dTVHeEZnVDRzR0ZNQTV4YjFNZmZKYjJIcG9mWnJWMEFBYWNiUDBVSlpLMlljOEllNlU2RTlvd0NiVkFZbmNlTmMzTXROMjdTX19md3VNMktmQ3Z4RWxjMGVoblUydWpNTWQ4LWJWMUk5Rl9LNHU3aFVqbVlQX1pNcVQxMk…
VERU Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9UdDE5YkRsU0FNenFvU3FyMEFDUURkSWpzeGNGTVBpek5id0czeXQxVDVRbjA2NlhNNTI4THhDUmtnZlp0ZkxBRks3enVPSDNGck5QUlAxTVJjcXEwZ2RmOU5FckdBV3Yxc0h0RHRaTjNhTEhnU0N4NjNR?oc=5" target="_blank">VER…
Why is Veru stock rising 10% today? - Investing.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQV0p2Y0wwaF92NGtvOFZsUExOZTRndDhXUDVBQVFXR1IwamNjRnNLOVRBVmM0bDYyOEZ0bHE1TVhhWldVakRNdk9EejdtendoY0k2M0JWeVFhbVdBVDZXY0dDSTVwWklmbkNGQlpaQ2NtWS1OblFod3gtNXpUMnBNTkYwajJiQ3JvcmpiZl…
Veru And 2 Other Intriguing Penny Stocks To Watch - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNbmh4Nkx1RVlxSEd0dEUwWnF2c1owOHpaU3NpcjhsclJMQnl1ZURlWG1feEZncWJrYzlIQXlfVHA4a3JxODZDX3RTNml6d0V1dE11Zlo2d1VqazB1amQxNGs0bXFsZXdvSnBFMldTaU9JelZJSEdUT0dQaURzcWZnRnp6MWRpQ0pHakhtNV…
VERU — Frequently Asked Questions
What is the current share price of Veru Inc. (VERU)?
As of 2026-09-19 21:16 PDT, Veru Inc. (VERU) trades at $2.58 on NasdaqCM. Its 52-week range is $2.09 to $4.43.
What is the market capitalisation of VERU?
Veru Inc. (VERU) has a market capitalisation of $43.99M on NasdaqCM.
What is the P/E ratio of VERU?
VERU trades at a trailing price-to-earnings (P/E) ratio of -4.23. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.45.
What is the return on equity (ROE) of VERU?
VERU has a return on equity (ROE) of -64.54%.
Is VERU a good stock to buy?
This page provides a data-driven analysis of Veru Inc. (VERU), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.